AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
Small Cell Lung Cancer in 2026: Consolidation IO Is Standard, Tarlatamab Has Full Approval, and the Maintenance Era Has Arrived
By Millie Das, MD
SCLC in 2026: consolidation durvalumab is standard in limited-stage disease, tarlatamab has full FDA approval, lurbinectedin maintenance is available, and antibody-drug conjugates are advancing in late-stage trials.
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Milk Thistle and Cancer: Why the Warning Label Exists
By The Cancer News Team
The milk thistle cancer warning is usually a California Prop 65 disclosure about trace heavy metals, not proof of harm. Learn the separate estrogen concern for hormone-sensitive cancers and treatment interactions.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
The Post–CAR-T Playbook: What Comes Next?
By Bhagirathbhai Dholaria, MD
CAR-T cures fewer than half of patients with relapsed large B-cell lymphoma, and outcomes after CAR-T failure depend heavily on when relapse occurs
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.